Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

BioMarin Pharmaceutical: Clinical Trials & FDA Approval Profile

BioMarin Pharmaceutical (San Rafael, CA) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (5 recruiting now), 5 completed protocols, and 8 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.0%
Median Closed Enrollment vs National (145 pts)21 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for BioMarin Pharmaceutical
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)14 (5)
Completed vs Stopped Early5 / 1 (5.0%)
Median Closed Actual Enrollment21 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals8 (2 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With BioMarin Pharmaceutical
Hospital Research SiteLocationShared Protocols
Northwestern Memorial and Lurie Cancer CenterChicago, IL8
Children's National Medical CenterWashington D.C, DC4
Cincinnati Children's Hospital Medical CenterCincinnati, OH4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by BioMarin Pharmaceutical
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07441876Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPhase II/IIIRECRUITING
NCT07126262A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsPhase IIRECRUITING
NCT06382155A Phase 2 Study of Vosoritide in Children With Idiopathic Short StaturePhase IIRECRUITING
NCT03989947An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaPhase IIACTIVE NOT RECRUITING
NCT06668805A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentPhase IIACTIVE NOT RECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the BioMarin Pharmaceutical Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI